Rob Rutledge, MD, who has won awards for health promotion with a focus on psychosocial and spiritual oncology, engaged participants’ minds and bodies with his presentation on The Mind-Body-Spirit Connection in your WM Journey.
Ismail Sharif, MD, FRCPc, explained how patients at the Halifax Hematology Clinic were diagnosed, the current treatment options available in Canada, and the importance of clinical trials to develop new therapies.
Shirley D’Sa, MD, author of the definitive Guide to Lymphoplasmacytic Lymphoma and Waldenstrom’s Macroglobulinema, kicked off the programme by explaining the basics of WM and the various complications that can arise.
Zachary Hunter, PhD, concluded the proceedings with the latest news in WM, including findings from the recent International Workshop on WM, held in New York in mid-October, 2018.
2018 WM Foundation Canada (WMFC) Educational Forum»
The first-ever Waldenstrom’s Macroglobulinemia Foundation of Canada’s (WMFC) educational forum in Halifax, Nova Scotia on October 27 provided four dozen patients, family members and hematology nurses the opportunity to learn from and speak with international and local WM experts, and to establish and to renew friendships.
Chairs: Judith Trotman (Australia) and Jorge Castillo (USA)
Overview of Novel Agents in Development for WM
Update of Novel Agent Clinical Trials in WM:
Phase II Study of the BTK-inhibitor Acalabrutinib in previously-treated WM patients
Phase II Study of the BTK-inhibitor Zanubrutinib in symptomatic WM patients
Phase II Study of the BCL2-inhibitor Venetoclax in previously treated WM patients
Phase I/II Study of the CXCR4-inhibitor Ulocuplomab plus ibrutinib in symptomatic WM
Chairs: Steven Treon (USA) and Meletios Dimopoulos (Greece)
Overview of Ibrutinib Therapy in WM
Update of ibrutinib clinical trials in WM:
Ibrutinib monotherapy in treatment-naïve WM patients
Long term follow-up of ibrutinib monotherapy in previously-treated WM patients:Update of pivotal trial
Ibrutinib monotherapy in rituximab-refractory WM patients
Randomized clinical trial of ibrutinib/rituximab versus rituximab in symptomatic WM patients
What are the mechanisms of resistance to ibrutinib in WM?
Chairs: Stathis Kastritis (Greece) and MJ Kersten (Netherlands)
Overview of Proteasome Inhibitor Activity in WM
Update of proteasome-inhibitor clinical trials in WM:
Long term follow-up of Bortezomib, Dexamethasone and Rituximab as frontline therapy in WM
Long term follow-up of Carfilzomib, Dexamethasone and Rituximab as frontline therapy in WM
Prospective Study of Ixazomib, Dexamethasone, Rituximab as frontline therapy in WM
Proteasome-inhibitors in previously treated WM
Chairs: Eva Kimby (Sweden) and Shirley D’Sa (UK).
Overview of rituximab alone and in combination in WM
Update of rituximab clinical trials in WM:
Bendamustine and Rituximab as first line therapy in WM
Randomized clinical trial of BCR vs. FCR as frontline therapy in WM patients
Rituximab Maintenance or Observation in WM
Activity of Rituximab in patients with MAG positive peripheral neuropathy
Keynote Address: Impressions of my father, Jan G. Waldenstrom, Anders Waldenstrom M.D. (Sweden)
Chairs: Zachary Hunter (USA) and Marzia Varretoni (Italy).
Overview of key genomic findings in WM
How do MYD88 mutations impact WM cell growth and survival?
Are MYD88 mutations by themselves sufficient to cause WM?
How do CXCR4 mutations impact WM cell growth and survival?
How important are TP53 mutations in WM?
What are the treatment implications for mutations found in WM?
What genomic findings accompany disease transformation in WM?